Crinetics Pharmaceuticals, Inc. (CRNX)

53.14 +0.37 (+0.70%) At close: 04:00PM EDT

Crinetics Pharmaceuticals, Inc.

6055 Lusk Boulevard
San Diego, CA 92121
United States
858 450 6464
https://www.crinetics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 290

Key executives

Name	Title	Pay	Exercised	Year born
Dr. R. Scott Struthers Ph.D.	Founder, President, CEO & Director	978.34k	5.65M	1963
Dr. Stephen F. Betz Ph.D.	Founder & Chief Scientific Officer	672.66k	N/A	1966
Mr. Marc J. C. Wilson	Chief Financial Officer	642.25k	408.5k	1979
Mr. Jeff E. Knight	Chief Operating Officer	657.31k	N/A	1971
Dr. Alan S. Krasner M.D.	Chief Endocrinologist	653.92k	125.93k	1963
Mr. James Hassard	Chief Commercial Officer	623.5k	N/A	1966
Gayathri Diwakar	Head of Investor Relations	N/A	N/A	N/A
Ms. Garlan Adams	General Counsel & Corporate Secretary	N/A	N/A	N/A
Ms. Adriana Cabre M.B.A.	Chief Human Resources Officer	N/A	N/A	N/A
Mr. Kevin Capps	Head of Intellectual Property	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Corporate governance

Crinetics Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 October 2024 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.